Sydney cancer medtech startup Lumonus, has added an additional $3 million to its Series B, four months on, to take the total raised to $28 million.
Brandon Capital and Investible joined the round, led by Aviron Investment Management with support from existing investor Oncology Ventures, which backed a Seed round in March 2025. The initial $25m Series B raise was announced last November.
The clinical care platform, founded in 2024, uses AI for radiation oncology workflow automation and is used in the US, Australia and Europe. Clinicians have used it consult and prescribe on more than 280,000 cancer treatments, automating more than 75,000r treatment plans.
The funds will be used to expand the US go-to-market and clinical success teams, clinical informatics capabilities, and improve its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, for more personalised, data-driven care.
Lumonus CEO Keith Hansen said oncology (cancer diagnosis and treatment) is at an inflection point
“Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace,” he said
“By combining AI-native architecture, a comprehensive end-to-end workflow approach, and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way.”
